World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
74
Citations
22049
World Ranking
1564
National Ranking
132

Overview

Anton Pozniak is affiliated with the London School of Hygiene & Tropical Medicine in the United Kingdom, with a research focus primarily in the field of Medicine.

Their work centers around infectious diseases, emergency medicine, virology, epidemiology, and surgery. The core themes of their research involve HIV/AIDS, with particular emphasis on HIV/AIDS research and interventions, drug development and treatment for HIV, HIV-related health complications and treatments, and the intersection of HIV with drug use and sexual risk. Additional topics include Pneumocystis jirovecii pneumonia detection and treatment, as well as clinical research related to COVID-19.

Anton Pozniak has published extensively in several scientific journals. The most frequent publication venues include:

  • The Lancet HIV
  • AIDS
  • Journal of Antimicrobial Chemotherapy
  • HIV Medicine
  • Clinical Infectious Diseases

The following are selected recent papers authored or coauthored by Anton Pozniak, showcasing the range and focus of their research:

  • Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications, 2022, Clinical Pharmacology & Therapeutics
  • Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV, 2021, Nature Communications
  • Cognitive impairment in people living with HIV: consensus recommendations for a new approach, 2023, Nature Reviews Neurology
  • Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial, 2021, The Lancet HIV
  • BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022, 2022, HIV Medicine

Frequent collaborators include several researchers with whom Anton Pozniak has coauthored multiple publications. These coauthors include:

  • Christoph Stephan, with 22 joint publications
  • Marta Boffito, with 14 joint publications
  • Giovanni Guaraldi, with 12 joint publications
  • Mar Masiá, with 12 joint publications
  • Laura Waters, with 11 joint publications

Best Publications

  • Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

    Joel E. Gallant;Schlomo Staszewski;Anton L. Pozniak;Edwin DeJesus

  • Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

    Joel E. Gallant;Edwin Dejesus;José R. Arribas;Anton L. Pozniak

  • British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

    B G Gazzard;Jane Anderson;Abdel Babiker;Marta Boffito

  • Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

    Melissa D. Simek;Wasima Rida;Frances H. Priddy;Pham Pung

  • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

    Paul E Sax;David Wohl;Michael T Yin;Frank Post

  • Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

    Gerd Fätkenheuer;Anton L Pozniak;Margaret A Johnson;Andreas Plettenberg

  • Loss of blood CD11c+ myeloid and CD11c−plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load

    Heather Donaghy;Anton Pozniak;Brian Gazzard;Nad Qazi

  • Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

    Gillian L. Dean;Simon G. Edwards;Natalie J. Ives;Gail Matthews

  • Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission

    Linda Gail Bekker;Linda Gail Bekker;George Alleyne;Stefan Baral;Javier Cepeda

  • Episodic Sexual Transmission of HIV Revealed by Molecular Phylodynamics

    Fraser Lewis;Gareth J Hughes;Andrew Rambaut;Anton Pozniak

  • European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults

    N Clumeck;A Pozniak;F Raffi

  • Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

    Mike Westby;Marilyn Lewis;Jeannette Whitcomb;Mike Youle

  • Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

    Linda Wittkop;Huldrych F Günthard;Frank de Wolf;David Dunn

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012

    Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

    Pedro Cahn;Anton L Pozniak;Horacio Mingrone;Andrey Shuldyakov

  • Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

    Paul E. Sax;Anton Pozniak;M. Luisa Montes;Ellen Koenig

  • Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades.

    Jacob Levi;Alice Raymond;Anton Pozniak;Pietro Vernazza

  • Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy-Naive and -Experienced Patients Coinfected with HIV-1 and Hepatitis B Virus

    Gregory J. Dore;David A. Cooper;Anton L. Pozniak;Edwin DeJesus

  • Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.

    Jose R. Arribas;Anton L. Pozniak;Joel E. Gallant;Edwin DeJesus

  • Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

    Anton L. Pozniak;Joel E. Gallant;Joel E. Gallant;Edwin DeJesus;Jose R. Arribas;Jose R. Arribas

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).

    Ian Williams;Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.

    Kathleen Squires;Anton L. Pozniak;Gerald Pierone;Corklin R. Steinhart

  • Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

    Anton Pozniak;Jose R. Arribas;Joseph Gathe;Samir K. Gupta

  • Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

    Christine Katlama;Roberto Esposito;Jose M Gatell;Jean-Christophe Goffard

Frequent Co-Authors

Marta Boffito
Marta Boffito Imperial College London
Brian Gazzard
Brian Gazzard St Bartholomew's Hospital
Mark Nelson
Mark Nelson University of Vermont
David Back
David Back University of Liverpool
Graeme Moyle
Graeme Moyle Chelsea and Westminster Hospital NHS Foundation Trust
Andrew Hill
Andrew Hill University of Liverpool
Saye Khoo
Saye Khoo University of Liverpool
David Dunn
David Dunn University College London
Alan Winston
Alan Winston Imperial College London
Deenan Pillay
Deenan Pillay University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in microbiology, exploring related online degrees can broaden career opportunities. Many students complement their studies with programs that focus on healthcare administration or public health. For example, pursuing an online medical billing and coding certificate fast can provide a quick pathway into the administrative side of healthcare, which is closely related to laboratory work and medical data management.

Additionally, if you are considering expanding your expertise in health sciences, there are many online medical programs available that offer flexible learning options. These programs often include courses that align with microbiology, such as immunology and infectious diseases.

For those looking to make an impact on community health, enrolling in some of the online mph programs easy to get into can be a strategic choice. Public health degrees incorporate microbiology principles to address disease prevention and health promotion on a larger scale.

Moreover, careers like becoming a certified child life specialist integrate knowledge of healthcare environments, which microbiologists may support. Researching the certified child life specialist salary and career requirements can help guide professionals interested in multidisciplinary healthcare sectors.

Best Scientists Citing Anton Pozniak

Trending Scientists